Bumin hospital
Seoul, South Korea
NCT Number: NCT07297940
This clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01 at fasting state.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Phase 1
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single dose administration (DA-1229 one tablet once a day)
single dose administration (DA-1229_01-R one tablet once a day)
Time frame: pre-dose~72 hours post-dose
Area Under the Curve
Time frame: pre-dose~72 hours post-dose
Maximum Plasma Concentration
Dong-A ST Co., Ltd.
Industry
An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Study to Evaluate the Pharmacokinetics and Safety of DA-1229_01 in Healthy Subjects at Fasting State
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06840925
Healthy
Melbourne, Victoria, Australia
View Trial DetailsNCT01866852
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT05370222
Behavior, Behavior, Animal
Clermont-Ferrand, AURA, France
View Trial DetailsNCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial Details